Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 6,690 matching trials from the live ClinicalTrials.gov search.

Filters: Stanford, California Clear all

Conditions: Osteoarthritis
Interventions: TDS-943 (topical diclofenac sodium 4% spray), celecoxib, placebo; Drug · Other
Lead sponsor: Mika Pharma GmbH; Industry
Eligibility: 40 Years and older
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 49
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 42 more

Conditions: HIV Infections
Interventions: Abacavir sulfate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 29
States / cities: Los Angeles, California • Menlo Park, California • San Jose, California + 19 more

Conditions: Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Interventions: Prostatic artery embolization; Device
Lead sponsor: Andrew Picel; Other
Eligibility: 45 Years to 85 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: HIV Infections, Peripheral Nervous System Diseases
Interventions: Acetyl-L-carnitine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 10
States / cities: Palo Alto, California • Atlanta, Georgia • Honolulu, Hawaii + 5 more

Conditions: Endometrial Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions: cisplatin, doxorubicin hydrochloride, low-LET photon therapy; Drug · Radiation
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1992
U.S. locations: 58
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 46 more

Conditions: Breast Cancer
Interventions: Placebo, GLSI-100; Biological
Lead sponsor: Greenwich LifeSciences, Inc.; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 2,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 51
States / cities: Mobile, Alabama • Goodyear, Arizona • Tucson, Arizona + 44 more

Conditions: Diabetes Mellitus
Interventions: Navigator Continuous Glucose Monitor; Device
Lead sponsor: Stanford University; Other
Eligibility: 7 Years to 20 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2)
Interventions: TAK-994, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 36
States / cities: Alabaster, Alabama • Phoenix, Arizona • Bellflower, California + 31 more

Conditions: Social Anxiety Disorder
Interventions: No intervention; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Medial Malleolus Fractures
Interventions: Fixation by Acutrak headless screw, Fixation by headed screws, plates, and or wires; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 3
States / cities: Palo Alto, California • Sacramento, California • Boston, Massachusetts

Conditions: Propionic Acidemia, Methylmalonic Acidemia
Interventions: N-carbamylglutamate, Standard of Care; Drug · Other
Lead sponsor: Mendel Tuchman; Other
Eligibility: 1 Hour to 4 Weeks
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 7
States / cities: Los Angeles, California • Palo Alto, California • Aurora, Colorado + 4 more

Conditions: Psoriatic Arthritis
Interventions: Placebo, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 642 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 72
States / cities: Mobile, Alabama • Mesa, Arizona • Peoria, Arizona + 65 more

Conditions: Lymphoma, Non-Hodgkin, Leukemia, Blood and Marrow Transplant (BMT), Lymphomas: Non-Hodgkin
Interventions: ablative allogeneic hematopoietic cell transplantation; Procedure
Lead sponsor: Stanford University; Other
Eligibility: Up to 50 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1989 – 2009
U.S. locations: 1
States / cities: Stanford, California

Conditions: Head and Neck Cancers- Squamous Cell, Head and Neck Cancer, Solid Tumors, HNSCC, SCC - Squamous Cell Carcinoma, SCCHN, Head Neck Cancer, Head and Neck Squamous Cell Cancer, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head And Neck, Squamous Cell Head and Neck Carcinoma, Oral Cavity, Oral Cavity Carcinoma
Interventions: VRP-encapsulated saRNA encoding IL-12 (1 x 10^9 viral particles per injection), Pembrolizumab (KEYTRUDA®), VRP-encapsulated saRNA encoding IL-12 (3 x 10^8 viral particles per injection); Biological · Drug
Lead sponsor: VLP Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Acute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk Factors, Chronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic Phase, Myelodysplastic Syndrome (MDS) - High and Intermediate Risk, Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL) - Refractory
Interventions: CliniMACS System; Device
Lead sponsor: Ginna Laport; Other
Eligibility: 18 Years to 50 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa
Interventions: LZRSE-Col7A1 Engineered Autologous Epidermal Sheets; Biological
Lead sponsor: Abeona Therapeutics, Inc; Industry
Eligibility: 13 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2022
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Interventions: VK-2019; Drug
Lead sponsor: Cullinan Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Stanford, California • Houston, Texas

Conditions: Stroke Recurrence, Myocardial Infarction, Vascular Death, Ischemic Stroke, TIA (Transient Ischemic Attack), Stroke (CVA) or Transient Ischemic Attack, Recurrent Stroke
Interventions: Cilostazol 100 mg Tablets, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 40 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 52
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 41 more

Conditions: Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Distal Bile Duct Cancer AJCC v8, Stage IIIA Gallbladder Cancer AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Distal Bile Duct Cancer AJCC v8, Stage IIIB Gallbladder Cancer AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Stage IVA Gallbladder Cancer AJCC v8, Stage IVB Gallbladder Cancer AJCC v8, Unresectable Extrahepatic Bile Duct Carcinoma, Unresectable Gallbladder Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Cisplatin, Gemcitabine Hydrochloride, Nab-paclitaxel; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 692
States / cities: Anchorage, Alaska • Goodyear, Arizona • Kingman, Arizona + 448 more

Conditions: Male Infertility
Interventions: Antioxidant Supplement, Placebo; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 10
States / cities: Los Angeles, California • San Francisco, California • Sunnyvale, California + 7 more

Conditions: Depressive Disorder, Depression, Depressive Disorder, Major, Depressive Episode, Major Depressive Disorder
Interventions: Synchronized Transcranial Magnetic Stimulation (sTMS), Sham Stimulation; Device
Lead sponsor: Wave Neuroscience; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 14
States / cities: La Jolla, California • Los Angeles, California • Stanford, California + 11 more

Conditions: Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions: EUR-1008 (APT-1008); Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: Up to 7 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • Oakland, California + 11 more

Conditions: Chronic Pain, Pediatric Disorder, Neuropathic Pain, Nociceptive Pain
Interventions: [18F]FTC-146; Drug
Lead sponsor: Stanford University; Other
Eligibility: 11 Years to 18 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Stanford, California

Conditions: Bladder Cancer
Interventions: Gemcitabine,, Cisplatin, Cetuximab; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 14
States / cities: Duarte, California • Los Angeles, California • Stanford, California + 11 more

Search by objective public record fields.

Study Evaluating the Efficacy and Safety of Topical Diclofenac Spray in Osteoarthritis of the Knee: Trial II

Effectiveness of the Early Addition of Abacavir to an Anti-HIV Drug Combination

Prostatic Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia (BPH)

Acetyl-L-Carnitine for the Treatment of NRTI-Associated Peripheral Neuropathy

Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

Reversal of Hypoglycemia Unawareness Using Continuous Glucose Monitoring

A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy

Social Anxiety Virtual Reality Study

Clinical Trial Evaluating Acutrak Headless Compression Screw Fixation of Medial Malleolus Fractures

Long-term Outcome of N-Carbamylglutamate Treatment in Propionic Acidemia and Methylmalonic Acidemia

A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug

Allo BMT in Advanced Leukemia or High Grade Lymphoma

Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer

Haploid Allogeneic Transplant Using the CliniMACS System

Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa

Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)

Cilostazol for Prevention of Recurrent Stroke Trial

Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

Males, Antioxidants, and Infertility Trial

Adaptive Design Study of NEST sTMS in Subjects With Major Depressive Disorder

Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

PET/MRI in the Diagnosis of Pediatric Chronic Pain

Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer